Dr RC Mishra

Hello,
Welcome to my website. I am Ram Chandra Mishra, PhD in Organic and Medicinal Chemistry from Central Drug Research Institute, Lucknow, INDIA. Currently, I am at Biology Department of Georgia State University and working on the design and development of natural product based compounds targeting Tubulin Dynamics as anticancer agents. More about me…

नमस्ते!

हमारे जाल स्थल पर आपका स्वागत है। मैं, राम चन्द्र मिश्र, ने केन्द्रीय औषधि अनुसंधान संस्थान लखनऊ से पी एच डी की उपाधि अर्जित की है। वर्तमान में जार्जिया राज्य विश्विद्यालय के जीव विज्ञान विभाग मे प्राकृतिक उत्पादों पर आधारित कैंसर निरोधी औषधियो की अभिकल्पना और विकास मे संलग्न हूँ।  मेरे बारे मे और…

Related reading

• Design, synthesis and biological evaluation of a novel series of anthrapyrazoles linked with netropsin-like oligopyrrole carboxamides as anticancer agents (kmistry.info)

Thomson Reuters made the Endnote X4 available to work with Office 2010 along with some more features.
Untill I get a licensed version from the university a 30 day trial version can be evaulated.

Adenine based acyclic-nucleotides as novel P2X3 receptor ligands

Volpini Rosaria; Mishra, RC; Kachare DD; Dalben Diego; Catia Lambertucci; Ippolito Antonini; Vittori sauro; Marucci Gabriella and Nistri Andrea

Abstract:

A new series of acyclic nucleotides based on the adenine skeleton and bearing in 9-position a phosphorylated four carbon chain has been synthesized. Various substituents were introduced in 2-position of the adenine core. The new compounds were evaluated on rat P2X₃ receptors, using patch clamp recording from HEK transfected cells and the full P2X₃ agonist α,β-meATP as reference compound. The results suggest that certain acyclic nucleotides, in particular compounds 28 and 29, are endowed with modest partial agonism on P2X₃ receptors. This is an interesting property that can depress the function of P2X₃ receptors, whose activation is believed to be involved in a number of chronic pain conditions including neuropathic pain and migraine. In fact, the new acyclic nucleotides are able to persistently block (by desensitization) P2X₃ receptor activity after a brief, modest activation, yet leaving the ability of sensory neurons to mediate responses to standard painful stimuli via a lower level of signaling.

Full Text HTML Hi-Res PDF[891 KB] PDF w/ Links[815 KB]

Adenosine A2A Receptor Antagonists: New 8-Substituted 9-Ethyladenines as Tools for in vivo Rat Models of Parkinson’s Disease

Rosaria Volpini, Prof., Diego Dal Ben, Dr., Catia Lambertucci, Dr., Gabriella Marucci, Prof. Dr., Ram Chandra Mishra, Dr., Anna Teresa Ramadori, Dr., Karl-Norbert Klotz, Prof., Maria Letizia Trincavelli, Dr. , Claudia Martini, Prof., Gloria Cristalli, Prof.

Abstract:

A new series of 8-substituted 9-ethyladenine derivatives has been synthesized and tested at rat and human adenosine receptors. Binding data demonstrates that some compounds could represent new tools suitable for in vivo studies in rat models of Parkinson’s disease and for the design of new molecules with improved affinity and selectivity at human AA2AR.
Clinical evidence has demonstrated that AA2AR antagonists could be an alternative approach to the treatment of Parkinson’s disease. Recently, three 9-ethyladenine derivatives bearing a bromine atom, an ethoxy group, and a furyl ring, respectively, in the 8-position have been reported to ameliorate motor deficits in rat Parkinson’s disease models, suggesting a potential therapeutic role for these compounds. Starting from these observations, a new series of 9-ethyladenine derivatives, bearing different substituents such as halogens, alkoxy groups, aromatic and heteroaromatic rings in the 8-position, were synthesized. Radioligand binding assays demonstrated that some of the new compounds bind rat AA2AR with higher affinity than the previously reported congeners and that there is a good correlation between binding to rat and human receptors. Hence, the new molecules could represent new tools suitable for the in vivo studies in rat models of Parkinson’s disease. Finally, a molecular docking analysis of the compounds was performed using a homology model of rat AA2AR, built using the human crystal structure as the template, and results are in agreement with the binding data.

Abstract |  References |  Full Text: HTML, PDF (Size: 518K)  | Related Articles | Citation Tracking

Related articles by Zemanta

• ‘Holy powder’ ingredient makes membranes behave for better health (scienceblog.com)
• Antioxidants help your body do a better job (thestar.com)
• News From The American Chemical Society , April 8, 2009 (medicalnewstoday.com)
• Turmeric The Miracle Spice (findmeacure.com)

Image via CrunchBase

TWITTER is a social networking tool that allows for real-time “micro-blogging” of short messages.

Now follow JACS’s twitter feed to stay in the loop about exciting JACS content, new features on JACS Beta, breaking news, upcoming events, and more. If you’d like to learn more about how Twitter works, please read the Twitter FAQ.

• Go to JACS’ Twitter Page for more info or connect to JACS on Twitter here
• ACS staff will be tweeting at the ACS National Meeting in Salt Lake City, March 22-26.

Reaxys, the new workflow solution for chemists, was released in January.

How can Reaxys help you as a researcher?

This innovative solution delivers exactly what you need.

• Synthesis planner: compares synthesis routes across publications and get a single overview enabling you to reach the appropriate route faster
• Superior reaction content: content from top journals and patent literature, selected by experts
• Filter and rank your search results according to preference – key properties, synthesis yield or other criteria
• Commercially available chemicals are flagged to directories (eMolecules and Symyx ACD): avoid synthesizing unnecessary compounds
• Additional search capabilities – you can generate structure queries from chemical names

Interested in more information or a free trial?
Take a look here for more details
Sincerely,
The Reaxys Team

Noscapine is an isoqiunoline alkaloid found in opium latex. Unlike most other alkaloids obtained from opium latex, noscapine is not sedative and has been used as antitussive drug in various countries. Recently, it has been introduced as an anti-mitotic agent. This drug can be used orally.When the resistance to other anti-cancer drugs such as paclitaxel menifests, noscapine might be effective. Therefore, noscapine and its analogs have great potential as novel anti-cancer agents.

Related articles

• Study Shows That A Cough Medicine Ingredient Could Effectively Treat Prostate Cancer (lockergnome.com)
• Tackling the Afghan heroin problem one pomegranate at a time (inquisitr.com)
• Neoadjuvant Herceptin Improves Event-free Survival in Locally Advanced Breast Cancer According to the international Phase III NOAH trial, the addition of Herceptin (trastuzumab) to neoadjuvant chemotherapy significantly improves event-free survival com (oncoblog.com)
• RAD001 Shows Promise In Tough-to-Treat Breast Cancer Patients (medicalnewstoday.com)

FDA’s decision “marks the dawn of a new era in medical therapeutics,” Thomas B. Okarma, president and CEO of Geron, said during a teleconference briefing. GRNOPC1 is intended to “permanently reverse disease pathology, not merely to temporarily relieve symptoms,” he noted.

via FDA Clears Stem Cell Clinical Trial | Chemical & Engineering News: Latest News.

Related articles:

• New Prez, New Era for Stem Cells?

It was the annual New Year’s Lunch Party for Rega Institute’s Med Chem Team at Groot Begijnhof.

As we were leaving after finishing our lunch, he was curious to see five indians in the team and asked, if I am from Pune (India). I told that I am from Lucknow, if he knows..He said he knows Saxena (Dr Anil Kumar Saxena, AK Saxena) there and has collaboration with around 60 labs in India. As I did my PhD from there (CDRI, Lucknow) and worked in Dr Saxena’s lab (I was working in Tripathi Research Group).

 Prof. Erik De Clercq

Bijzonder gasthoogleraar (Emeritus Professor), Department of Microbiology and Immunology

Since I came to Rega, I was very eager to see him